1,803 results match your criteria: "MS Center[Affiliation]"
Netw Neurosci
December 2024
Neuroradiology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
Multiple sclerosis (MS) is a neurodegenerative disease that affects the central nervous system. Structures affected in MS include the corpus callosum, connecting the hemispheres. Studies have shown that in mammalian brains, structural connectivity is organized according to a conservation principle, an inverse relationship between intra- and interhemispheric connectivity.
View Article and Find Full Text PDFAnn Clin Transl Neurol
December 2024
MS Center Amsterdam, Department of Anatomy and Neurosciences, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Objective: To assess the interrelationship between cortical lesions and cortical thinning and volume loss in people with multiple sclerosis within cortical networks, and how this relates to future cognition.
Methods: In this longitudinal study, 230 people with multiple sclerosis and 60 healthy controls underwent 3 Tesla MRI at baseline and neuropsychological assessment at baseline and 5-year follow-up. Cortical regions (N = 212) were divided into seven functional networks.
Brain
December 2024
Neuroimmunology Research Group, Netherlands Institute for Neuroscience, 1105BA, Amsterdam, The Netherlands.
Multiple sclerosis (MS) is a highly heterogeneous disease with varying remyelination potential across individuals and between lesions. However, the molecular mechanisms underlying the potential to remyelinate remain poorly understood. In this study, we aimed to take advantage of the intrinsic heterogeneity in remyelinating capacity between MS donors and lesions to uncover known and novel pro-remyelinating molecules for MS therapies.
View Article and Find Full Text PDFProstaglandins Leukot Essent Fatty Acids
December 2024
Center for Neuroscience, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, , Netherlands. Electronic address:
Lipid dyshomeostasis and neuroinflammation are key hallmarks of neuropsychiatric and neurodegenerative disorders, including major depressive disorder and Alzheimer's disease. In particular, polyunsaturated fatty acids (PUFAs) and their derivatives called oxylipins gained specific interest in this context, especially considering their capacity to orchestrate neuroinflammatory responses via direct modulation of microglia. The hippocampus and hypothalamus are crucial brain regions for regulating mood and cognition that are implicated in a variety of neuropsychiatric and neurodegenerative disorders and there is ample evidence for the sex-bias in risks for the development as well as sex-bias in the presentation of such psychiatric diseases, including the neuroinflammatory response.
View Article and Find Full Text PDFBiol Sex Differ
December 2024
Neuro-Immune Connections and Repair Lab, Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium.
Obesity is a growing pandemic that increases the risk for cardiovascular diseases, type 2 diabetes, and particularly in women also the risk of cancer and neurodegenerative disorders such as dementia and multiple sclerosis. Preclinical studies on obesity focus on male mice as they gain bodyweight faster and show a clear pro-inflammatory phenotype. Here, using male and female mice, we induced obesity by feeding a high fat diet (HFD), and compared adipose tissue (AT) inflammation at the same adiposity stage (% AT/bodyweight) between both sexes.
View Article and Find Full Text PDFJ Neuroinflammation
December 2024
Department of Molecular Cell Biology and Immunology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Microvascular brain endothelial cells tightly limit the entry of blood components and peripheral cells into the brain by forming the blood-brain barrier (BBB). The BBB is regulated by a cascade of mechanical and chemical signals including shear stress and elasticity of the adjacent endothelial basement membrane (BM). During physiological aging, but especially in neurological diseases including multiple sclerosis (MS), stroke, small vessel disease, and Alzheimer's disease (AD), the BBB is exposed to inflammation, rigidity changes of the BM, and disturbed cerebral blood flow (CBF).
View Article and Find Full Text PDFMult Scler
December 2024
EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA.
Background: CLASSIC-MS explored long-term outcomes of patients treated with cladribine tablets.
Objective: Assess long-term efficacy in patients previously enrolled in ORACLE-MS, a Phase III parent trial.
Methods: ORACLE-MS included patients with a first clinical demyelinating event (FCDE or clinically isolated syndrome) who received ⩾1 course of cladribine tablets or placebo.
Ann Clin Transl Neurol
December 2024
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, 02129, USA.
Objective: To quantify alterations in soma and neurite density imaging measures within and surrounding cortical lesions in people with multiple sclerosis using in vivo high-gradient diffusion MRI.
Methods: In this cross-sectional study, 41 people with multiple sclerosis and 34 age- and sex-matched healthy controls underwent 3 T high-gradient diffusion MRI. Cortical lesions were segmented on artificial intelligence-enabled double inversion recovery images.
Neurology
January 2025
From the Multiple Sclerosis Centre of Catalonia (Cemcat) & Neurology Department (N.M.-O., P.C.-M., N.B., A.V.-J., M.T., X.M., J.S.-G.), and Section of Neuroradiology (D.P., M.A., C.A., À.R.), Department of Radiology (IDI), Vall Hebron University Hospital, Barcelona; Neuroimaging Research Unit (P.V., M.M., A.M., P.P., M.A.R., M.F.), Division of Neuroscience, Neurology Unit, and Neurorehabilitation Unit (M.M., M.F.), IRCCS San Raffaele Scientific Institute, Milan, Italy; Multiple Sclerosis Center (MSC) (C.G., C.Z.), Department of Neurology, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences (C.G., C.Z.), Università della Svizzera Italiana (USI), Lugano, Switzerland; Faculty of Brain Sciences (F.B.), University College London Queen Square Institute of Neurology, University College London; National Institute for Health Research (F.B.), University College London Hospitals Biomedical Research Centre, United Kingdom; MS Center Amsterdam (F.B., M.M.S., E.M.M.S.), Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, the Netherlands; Clinic of Neurology (A. Gallo, A.B.), and MRI Research Center SUN-FISM (A. Gallo, A.B.), Second University of Naples, Italy; Queen Square MS Centre (O.C., F.D.A., M.C.Y.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London; National Institute for Health Research (O.C., F.D.A.), Biomedical Research Centre, University College London Hospitals; Nuffield Department of Clinical Neurosciences (J.P., L.M.), Oxford, United Kingdom; Department of Neurology (A. Gass, P.E.), Mannheim Center of Translational Neurosciences (MCTN), Medical Faculty Mannheim, Heidelberg University; Institute of Neuroradiology (C.L., B.B.), St. Josef-Hospital Bochum, Ruhr University Bochum, Germany; Vita-Salute San Raffaele University (P.P., M.A.R., M.F.); Neurology Unit (P.P., M.A.R., M.F.), and Neuropshysiology Service (M.F.), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Background And Objectives: In multiple sclerosis (MS), brain reserve serves as a protective factor against cognitive impairment. Previous research has suggested a structural counterpart in the spine-spinal cord reserve-seemed to be associated with physical disability. This study aimed to investigate the potential of the cervical canal area (CCaA) as a proxy for spinal cord reserve in a multicentric cohort of people with MS (PwMS).
View Article and Find Full Text PDFPharmacoepidemiol Drug Saf
December 2024
Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
Purpose: The purpose of this study was to describe the intensity and patterns of antibiotic drug use among people with multiple sclerosis (pwMS) in the Netherlands.
Methods: People with prevalent MS between 1 January 2018 and 31 December 2020 were identified using ambulatory hospital records from the PHARMO Database Network that contains routinely collected healthcare data from the Netherlands. Out-patient pharmacy dispensing data were used to assess type of antibiotic, dosage, and amounts dispensed.
Mult Scler Relat Disord
November 2024
Biogen, Cambridge, MA, USA. Electronic address:
Background: The randomized, phase 2 RENEW trial (NCT01721161) evaluated efficacy/safety of opicinumab (anti-LINGO-1) versus placebo in patients with first-episode unilateral acute optic neuritis (AON). Although no significant differences in the latency recovery of visual evoked potential (VEP) were observed between opicinumab and placebo groups in the intention to treat (ITT) population, the prespecified per-protocol (PP) population showed better recovery with opicinumab than with placebo. RENEWED (NCT02657915) was a one-visit, follow-up study 2 years after the last RENEW study visit (Week 32) designed to assess the long-term electrophysiological and clinical outcomes for participants previously enrolled and having received study treatment in RENEW.
View Article and Find Full Text PDFJ Neurol Neurosurg Psychiatry
December 2024
Neurology, MS Center ErasMS, Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands
Mult Scler Relat Disord
December 2024
Department of Neurology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam Neuroscience, MS Center Amsterdam, Amsterdam, The Netherlands; Amsterdam Public Health research institute, Quality of Care, The Netherlands.
Background: The rising prevalence estimates of multiple sclerosis (MS) globally underscore the imperative for up-to-date epidemiological data specific to the Netherlands.
Methods: Data from two Dutch healthcare databases (Nivel Primary Care Database and Vektis Database) comprising both general practices and hospital electronic health records in 2019 were combined to assess age- and sex-standardized MS prevalence and incidence estimates. Differences in prevalence estimates based on latitude and between primary versus secondary care records were examined.
Ann Phys Rehabil Med
December 2024
REVAL Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, Hasselt 3500, Belgium; UMSC, Hasselt/Pelt 3500/3900 Belgium.
JAMA Neurol
December 2024
Multiple Sclerosis Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Center location VUmc, Amsterdam, the Netherlands.
Importance: Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy.
Objective: To investigate whether first-line DMT can be safely discontinued in patients with long-term stable MS.
Mult Scler
December 2024
MS Center Amsterdam, Department of Anatomy & Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands.
Background: Literature on the intricate relationship between self-reported and objectively assessed cognitive functioning suggests a discrepancy between self-reported cognitive complaints (SCC) and actual test performance.
Objectives: To investigate the interplay between patient-reported outcome measures (PROMs) and objective cognitive functioning using network analysis in people with multiple sclerosis (PwMS).
Methods: We collected PROMs on anxiety, depression, fatigue and SCC, and cognitive functioning across six domains ( = 703 PwMS; 71% female, mean age = 46.
J Neurol Neurosurg Psychiatry
December 2024
Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.
Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our aim was to investigate the potential effect of DMT on disability worsening among patients with PPMS stratified by different disability trajectories.
View Article and Find Full Text PDFNeurology
January 2025
From the Department of Clinical Neurosciences (M.W.K., J.R.S.), University of Calgary, Alberta; Division of Neurology (L.V.K.), Department of Medicine, Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Ontario; Department of Medicine (D.W.), University of British Columbia Southern Medical Program, Kelowna; Division of Neurology (T.A.M., M.G.S.), Department of Medicine, University of Ottawa, The Ottawa Hospital Ottawa, Ontario, Canada; Department of Neurology (J.M.), Rijnstate Hospital, Arnhem; Department of Neurology (E.M.M.S., B.U.), MS Center Amsterdam, Amsterdam University Medical Centers, the Netherlands; Section on Statistical Planning and Analysis (A.S.), Department of Neurology, UT Southwestern Medical Center, Dallas; and Department of Biostatistics (G.R.C.), University of Alabama at Birmingham.
Background And Objectives: Disease-modifying treatments (DMTs) are a major unmet need in Parkinson disease (PD). To date, trials investigating DMT candidates in PD most often used a randomized controlled trial (RCT) design. Unfortunately, RCTs to date have not led to a breakthrough, in part because of the large sample sizes and length of follow-up required.
View Article and Find Full Text PDFNeurology
December 2024
From the Department of Neurology (P.D.C., S.S.), and Department of Biostatistics & Informatics (S.S.), University of Colorado Anschutz Medical Campus; University of Colorado School of Medicine Anschutz Medical Campus (R.D., P.W., E.E., B.V., E.M., K.V.N., A.M.C., A.L.P.); University of Colorado School of Medicine (R.F.), Aurora; School of Osteopathic Medicine (R.F.), Kanas City University, MO; University of Colorado School of Medicine Anschutz Medical Campus (R.V.C.); School of Medicine (R.V.C.), Aurora, CO; Renown Health (R.V.C.), Reno, NV; Rocky Mountain MS Center (K.V.N., A.L.P.), University of Colorado School of Medicine; and Skaggs School of Pharmacy and Pharmaceutical Sciences (K.V.N.), University of Colorado Anschutz Medical Campus, Aurora.
Commun Biol
November 2024
AIMS lab, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.
In multiple sclerosis (MS), working memory (WM) impairment can occur soon after disease onset and significantly affects the patient's quality of life. Functional imaging research in MS aims to investigate the neurophysiological underpinnings of WM impairment. In this context, we utilize a data-driven technique, the time delay embedded-hidden Markov model, to extract spectrally defined functional networks in magnetoencephalographic (MEG) data acquired during a WM visual-verbal n-back task.
View Article and Find Full Text PDFInt J Mol Sci
November 2024
Department of Neurology, First Faculty of Medicine, Charles University, 12008 Prague, Czech Republic.
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) mainly afflicting young women. Various steroids can influence the onset and development of the disease or, on the contrary, mitigate its course; however, a systematic review of steroidomic changes in MS patients is lacking. Based on the gas chromatography tandem mass spectrometry (GC-MS/MS) platform and, in the case of estradiol, also using immunoassay, this study performed a comprehensive steroidomic analysis in 25 female MS patients aged 39(32, 49) years compared to 15 female age-matched controls aged 38(31, 46) years.
View Article and Find Full Text PDFNeurol Sci
November 2024
Department of NEUROFARBA, University of Florence, Largo Piero Palagi, 1, Florence, 50139, Italy.
Objective: Cognitive impairment affects approximately 30% of pediatric onset Multiple Sclerosis (POMS) patients with a negative impact on everyday life. The aim of this study was to evaluate the feasibility and effectiveness of a home-based, computer-assisted training of attention in patients with POMS.
Methods: This was a randomized double-blind study.
Neurology
December 2024
From the Department of Radiology and Oncology (C.d.M.R., C.C.L.), Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP); LIM 44 (C.d.M.R., M.P.N., I.B.A., C.C.L.), Laboratory of Medical Investigation in Magnetic Resonance of the University of São Paulo, São Paulo, Brazil; MS Center Amsterdam (C.d.M.R., M.M.S.), Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, location VUmc, the Netherlands; Department of Neurology (S.L.A.-P., D.C.), Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP); Department of Epidemiology and Biostatistics (M.B.W.), Faculdade de Medicina, Universidade Federal do Rio Grande do Sul (UFRGS); Department of Epidemiology and Biostatistics (M.B.W.), School of Medicine, Pontifical Catholic University of Rio Grande do Sul (PUCRS), Brazil; MS Center Amsterdam (F.B.), Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, the Netherlands; and Queen Square MS Center (F.B.), Department of Neuroinflammation, Institute of Neurology, Faculty of Brain Sciences, and Centre for Medical Image Computing (CMIC) (F.B.), Department of Medical Physics and Biomedical Engineering, University College London (UCL), United Kingdom.
PLoS One
November 2024
Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
Background: Improving health-related quality of life (HRQoL) is an important disease management goal in persons with Multiple Sclerosis (PwMS). HRQoL decreases with increasing age and prolonged disease duration; other factors remain less understood.
Objective: To identify associations of multiple sclerosis (MS) disease characteristics and symptom burden with low HRQoL.
Introduction: Real-world studies in the USA report that 41-56% of patients with multiple sclerosis (MS) are ≥ 50 years old, yet data on their response to disease-modifying therapies (DMTs) is limited. Dimethyl fumarate (DMF) is an oral DMT approved for treating relapsing MS. This analysis evaluated the safety, efficacy, and immunophenotype changes of DMF in patients ≥ 50 years compared with patients < 50 years.
View Article and Find Full Text PDF